On November 19, Teva Pharmaceutical fell 4.19% in Regular Trading, trading at $40.485/share, with turnover of $52.3944 million.
The move followed the company’s announcement that Chief Medical Officer and Executive Vice President of Global Research and Development Eric Hughes is departing after accepting a position outside the company, prompting a leadership transition in a key innovation role.
Teva said Hughes will remain through the coming months to support the transition, while David Gardiner, head of innovative medicines and clinical development, will serve as R&D transition lead until a permanent successor is appointed. The company added that strategy, R&D priorities and expectations remain unchanged and that a search for a successor is underway. The reaction came shortly after Teva’s recent R&D day and innovation updates, making the management change a focal point for investors despite recent analyst price-target increases and the FDA approval of at-home use for Igalmi.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments